Author: "Chevalier-Place, A." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Chevalier-Place, A."' showing total 106 results

Start Over Author "Chevalier-Place, A."

106 results on '"Chevalier-Place, A."'

1. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

Author: Blanc-Durand, Félix, Yaniz-Galende, Elisa, Llop-Guevara, Alba, Genestie, Catherine, Serra, Violeta, Herencia-Ropero, Andrea, Klein, Christophe, Berton, Dominique, Lortholary, Alain, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Bonichon-Lamaichhane, Nathalie, Dubot, Coraline, Kurtz, Jean Emmanuel, de Rauglaudre, Gaëtan, Raban, Nadia, Chevalier-Place, Annick, Ferron, Gwenael, Kaminsky, Marie-Christine, Kramer, Claire, Rouleau, Etienne, and Leary, Alexandra
Published: 2023
Full Text: View/download PDF

2. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Author: Robelin, Patrick, Tod, Michel, Colomban, Olivier, Lachuer, Joel, Ray-Coquard, Isabelle, Rauglaudre, Gaëtan De, Joly, Florence, Chevalier-Place, Annick, Combe, Pierre, Lortholary, Alain, Hamizi, Salima, Raban, Nadia, Ferron, Gwénaël, Meunier, Jérôme, Berton-Rigaud, Dominique, Alexandre, Jérôme, Kaminsky, Marie-Christine, Dubot, Coraline, Leary, Alexandra, Malaurie, Emmanuelle, and You, Benoit
Published: 2020
Full Text: View/download PDF

3. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author: Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary
Published: 2023
Full Text: View/download PDF

4. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author: Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary
Published: 2023
Full Text: View/download PDF

5. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author: Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary
Published: 2023
Full Text: View/download PDF

6. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Author: Leman, Raphaël, primary, Muller, Etienne, primary, Legros, Angelina, primary, Goardon, Nicolas, primary, Chentli, Imène, primary, Atkinson, Alexandre, primary, Tranchant, Aurore, primary, Castera, Laurent, primary, Krieger, Sophie, primary, Ricou, Agathe, primary, Boulouard, Flavie, primary, Joly, Florence, primary, Boucly, Romain, primary, Dumont, Aurélie, primary, Basset, Noémie, primary, Coulet, Florence, primary, Chevalier, Louise-Marie, primary, Rouleau, Etienne, primary, Leitner, Katharina, primary, González-Martin, Antonio, primary, Gargiulo, Piera, primary, Lück, Hans-Joachim, primary, Genestie, Catherine, primary, Bogner, Gerhard, primary, Marth, Christian, primary, Petru, Edgar, primary, Reinthaller, Alexander, primary, Schauer, Christian, primary, Sevelda, Paul, primary, D'Hondt, Lionel, primary, Vergote, Ignace, primary, Vuylsteke, Peter, primary, Hietanen, Sakari, primary, Lindahl, Gabriel, primary, Mäenpää, Johanna, primary, Nøttrup, Trine Jakobi, primary, Puistola, Ulla, primary, Abadie-Lacourtoisie, Sophie, primary, Alexandre, Jérôme, primary, Boissier, Emilie, primary, Bourgeois, Hugues, primary, Chevalier-Place, Annick, primary, Combe, Pierre, primary, Costan, Cristina, primary, Dauba, Jérôme, primary, De Cock, Laure, primary, Desauw, Christophe, primary, Despax, Raymond, primary, Dohollou, Nadine, primary, Dubot, Coraline, primary, Fabbro, Michel, primary, Favier, Laure, primary, Floquet, Anne, primary, Follana, Philippe, primary, Tixidre, Claire Garnier, primary, Garnier, Georges, primary, Gladieff, Laurence, primary, Grenier, Julien, primary, Guillemet, Cécile, primary, Hardy-Bessard, Anne-Claire, primary, Kalbacher, Elsa, primary, Kaminsky, Marie-Christine, primary, Kurtz, Jean-Emmanuel, primary, Largillier, Rémy, primary, Lefeuvre-Plesse, Claudia, primary, Lesoin, Anne, primary, Levache, Charles-Briac, primary, L'Haridon, Tifenn, primary, Lortholary, Alain, primary, Lotz, Jean-Pierre, primary, Meunier, Jérôme, primary, Mousseau, Mirerille, primary, Mouret-Reynier, Marie-Ange, primary, Pautier, Patricia, primary, Petit, Thierry, primary, Provansal, Magali, primary, Pujade-Lauraine, Eric, primary, Raban, Nadia, primary, Ray-Coquard, Isabelle, primary, Rodrigues, Manuel, primary, Selle, Frédéric, primary, Sverdlin, Robert, primary, Tazi, Youssef, primary, You, Benoît, primary, Aktas, Bahriye, primary, Bauerschlag, Dirk Olaf, primary, Beck, Thomas, primary, Belau, Antje, primary, Bronger, Holger, primary, Buchholz, Stefan, primary, Buderath, Paul, primary, Burges, Alexander, primary, Canzler, Ulrich, primary, de Gregorio, Nikolaus, primary, Denschlag, Dominik, primary, Dieterich, Max, primary, Eichbaum, Michael, primary, El-Balat, Ahmed, primary, Emons, Günter, primary, Fasching, Peter, primary, Feisel-Schwickardi, Gabriele, primary, Frank, Matthias, primary, Friedrich, Michael, primary, Grischke, Eva-Maria, primary, Gropp-Meier, Martina, primary, Hanker, Lars, primary, Hannig, Carla, primary, Harter, Philipp, primary, Hasenburg, Annette, primary, Hellriegel, Martin, primary, Herwig, Uwe, primary, Heubner, Martin, primary, Hulde, Joachim, primary, Jackisch, Christian, primary, Kögel, Matthias, primary, Krieger, Peter, primary, Kühn, Thorsten, primary, Liebrich, Clemens, primary, Mallmann, Peter, primary, Marmé, Frederik, primary, Meier, Werner, primary, Möbus, Voker, primary, Mohamed, Omar Farag, primary, Nestle-Krämling, Carolin, primary, Neunhöffer, Tanja, primary, Oskay-Özcelik, Gülten, primary, Park-Simon, Tjoung-Won, primary, Rautenberg, Beate, primary, Rein, Daniel, primary, Ruhwedel, Wencke, primary, Runnebaum, Ingo, primary, Sagasser, Jacqueline, primary, Schmalfeldt, Barbara, primary, Schneeweiss, Andreas, primary, Schnelzer, Andreas, primary, Scholz, Heinz, primary, Sehouli, Jalid, primary, Sperfeld, Antje, primary, Steckkönig, Annette, primary, Strauß, Hans-Georg, primary, Tomé, Oliver, primary, Treustedt, Jörn, primary, Voß, Hermann, primary, Wischnik, Arthur, primary, Witteler, Ralf, primary, Wöckel, Achim, primary, Woeltjen, Hans-Heinrich, primary, Zorr, Andreas, primary, Bologna, Alessandra, primary, Colombo, Nicoletta, primary, Tognon, Germana, primary, Cinieri, Saverio, primary, Lorusso, Domenica, primary, Mosconi, Anna Maria, primary, Pignata, Sandro, primary, Savarese, Antonella, primary, Scambia, Giovanni, primary, Sorio, Roberto, primary, Zamagni, Claudio, primary, Fujiwara, Keiichi, primary, Fujiwara, Hiroyuki, primary, Kobayashi, Hiroaki, primary, Matsumoto, Takashi, primary, Nagao, Shoji, primary, Satoh, Toyomi, primary, Yonemori, Kan, primary, Yoshida, Hiroyuki, primary, Bratos, Raquel, primary, Caballero, Cristina, primary, Garica, Yolanda, primary, González-Martín, Antonio, primary, Alia, Eva Maria Guerra, primary, Hernando, Susana, primary, Herrero, Ana, primary, Lainez, Nuria, primary, Manso, Luis, primary, Martin, Cristina, primary, Murata, Eleonor, primary, Ortega, Eugenia, primary, Palacio, Isabel, primary, Poveda, Andres, primary, Romero, Ignacio, primary, Rubio, Maria Jesús, primary, and Vaur, Dominique, primary
Published: 2023
Full Text: View/download PDF

7. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

Author: Félix Blanc-Durand, Elisa Yaniz-Galende, Alba Llop-Guevara, Catherine Genestie, Violeta Serra, Andrea Herencia-Ropero, Christophe Klein, Dominique Berton, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Coraline Dubot, Jean Emmanuel Kurtz, Gaëtan de Rauglaudre, Nadia Raban, Annick Chevalier-Place, Gwenael Ferron, Marie-Christine Kaminsky, Claire Kramer, Etienne Rouleau, and Alexandra Leary
Subjects: Oncology, Obstetrics and Gynecology
Published: 2023

8. Corrigendum to “A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer”

Author: Blanc-Durand, Félix, primary, Yaniz-Galende, Elisa, additional, Llop-Guevara, Alba, additional, Genestie, Catherine, additional, Serra, Violeta, additional, Herencia-Ropero, Andrea, additional, Klein, Christophe, additional, Berton, Dominique, additional, Lortholary, Alain, additional, Dohollou, Nadine, additional, Desauw, Christophe, additional, Fabbro, Michel, additional, Malaurie, Emmanuelle, additional, Bonichon-Lamaichhane, Nathalie, additional, Dubot, Coraline, additional, Kurtz, Jean Emmanuel, additional, de Rauglaudre, Gaëtan, additional, Raban, Nadia, additional, Chevalier-Place, Annick, additional, Ferron, Gwenael, additional, Kaminsky, Marie-Christine, additional, Kramer, Claire, additional, Rouleau, Etienne, additional, and Leary, Alexandra, additional
Published: 2023
Full Text: View/download PDF

9. Supplementary Figure 9 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

10. Supplementary Table 2 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

11. Supplementary Table 4 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

12. Supplementary Table 5 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

13. Supplementary Table 3 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

14. Supplementary Table 1 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

15. Supplementary Figure 2 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

16. Supplementary Figure 7 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, primary, Tod, Michel, primary, Louvet, Christophe, primary, Lotz, Jean-Pierre, primary, Abadie-Lacourtoisie, Sophie, primary, Fabbro, Michel, primary, Desauw, Christophe, primary, Bonichon-Lamichhane, Nathalie, primary, Kurtz, Jean-Emmanuel, primary, Follana, Philippe, primary, Leheurteur, Marianne, primary, Piano, Francesco Del, primary, Ferron, Gwénael, primary, De Rauglaudre, Gaëtan, primary, Ray-Coquard, Isabelle, primary, Combe, Pierre, primary, Chevalier-Place, Annick, primary, Joly, Florence, primary, Leary, Alexandra, primary, Pujade-Lauraine, Eric, primary, Freyer, Gilles, primary, and Colomban, Olivier, primary
Published: 2023
Full Text: View/download PDF

17. Data from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Purpose:In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMination rate constant K (KELIM), calculated with the CA-125 longitudinal kinetics during the first 100 chemotherapy days, is a validated early marker of tumor chemosensitivity. The objective was to investigate the role of the chemosensitivity relative to the success of first-line medical–surgical treatment.Experimental Design:The CA-125 concentrations were prospectively measured in the randomized phase II trial CHIVA (NCT01583322, carboplatin–paclitaxel regimen ± nintedanib, and IDS, n = 188 patients). The KELIM predictive value regarding the tumor response rate, likelihood of complete IDS, risk of subsequent platinum-resistant relapse (PtRR), progression-free survival (PFS), and overall survival (OS) was assessed using univariate and multivariate tests.Results:The data from 134 patients were analyzed. KELIM was an independent and major predictor of subsequent PtRR risk, and of survivals. The final logistic regression model, including KELIM [OR = 0.13; 95% confidence interval (CI), 0.03–0.49] and complete IDS (no vs. yes, OR = 0.30; 95% CI, 0.11–0.76) highlights the preponderant role of chemosensitivity on the success of the first-line treatment. In patients with highly chemosensitive diseases, the patient prognosis was driven more by the chemotherapy-induced antitumor effects than by the surgery.Conclusions:The tumor-primary chemosensitivity, assessed by the modeled CA-125 KELIM calculated during neoadjuvant chemotherapy (http://www.biomarker-kinetics.org/CA-125-neo), may be a major parameter to consider for decision-making regarding IDS attempt, and selecting patients for treatments meant to reverse the primary chemoresistance.See related commentary by May and Oza, p. 4432
Published: 2023

18. Supplementary Figure 5 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: A. Completeness of interval debulking surgery (IDS) according to standardized (std) KELIM value. Wilcoxon P < 0.01. B. Logistic regression curve regarding the probability of complete surgery according to continuous std KELIM values.
Published: 2023

19. Supplementary Table 4 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Supplementary Table 4
Published: 2023

20. Supplementary Figure 7 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Explorative analyses of overall survival according to standardized KELIM terciles (upper vs intermediate + lower) and completeness of interval debulking surgery. Med.: Median; IDS: interval debulking surgery; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Published: 2023

21. Supplementary Figure 1 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Flowchart of the study. IDS: Interval debulking surgery; PFS: progression-free survival; OS: overall survival.
Published: 2023

22. Supplementary Figure 6 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Explorative analyses of progression-free survival according to standardized KELIM terciles (upper vs intermediate + lower) and completeness of interval debulking surgery. Med.: Median; std: standardized; IDS: interval debulking surgery; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Published: 2023

23. Supplementary Figure 2 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Goodness-of-fit plots. Predicted versus observed CA-125 concentrations are shown for the population (left panel) and for individuals (right panel). Black line: identity line.
Published: 2023

24. Supplementary Table 5 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Supplementary Table 5
Published: 2023

25. Supplementary Table 3 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Suppl Table 3
Published: 2023

26. Supplementary Figure 4 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Receiver Operating Characteristics curve regarding Complete interval debulking surgery (Yes vs No) according to KELIM. Selection of the best predictive KELIM cut-off using Youden index.
Published: 2023

27. Supplementary Figure 9 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Explorative analyses of overall survival according to standardized KELIM terciles (upper vs intermediate + lower) and disease risk-group adjusted from Oza et al. Med.: Median; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Published: 2023

28. Supplementary Figure 8 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Explorative analyses of progression-free survival according to standardized KELIM terciles (upper vs intermediate + lower) and disease-risk groups, adjusted from Oza et al. Med.: Median; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Published: 2023

29. Supplementary Table 1 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Supplementary Table 1
Published: 2023

30. Supplementary Table 2 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Supplementary Table 2
Published: 2023

31. Supplementary Figure 3 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Olivier Colomban, Gilles Freyer, Eric Pujade-Lauraine, Alexandra Leary, Florence Joly, Annick Chevalier-Place, Pierre Combe, Isabelle Ray-Coquard, Gaëtan De Rauglaudre, Gwénael Ferron, Francesco Del Piano, Marianne Leheurteur, Philippe Follana, Jean-Emmanuel Kurtz, Nathalie Bonichon-Lamichhane, Christophe Desauw, Michel Fabbro, Sophie Abadie-Lacourtoisie, Jean-Pierre Lotz, Christophe Louvet, Michel Tod, Patrick Robelin, and Benoit You
Abstract: Visual predictive checks. Purple areas represent the 95% confidence intervals of the 10th, 50th, and 90th percentiles of simulated data. Red lines represent the median (solid line), and the 10th and 90th percentiles (dashed lines) of the observations.
Published: 2023

32. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Author: Heudel, Pierre, primary, Frenel, Jean-Sébastien, additional, Dalban, Cécile, additional, Bazan, Fernando, additional, Joly, Florence, additional, Arnaud, Antoine, additional, Abdeddaim, Cyril, additional, Chevalier-Place, Annick, additional, Augereau, Paule, additional, Pautier, Patricia, additional, Chakiba, Camille, additional, You, Benoit, additional, Lancry-Lecomte, Laurence, additional, Garin, Gwenaelle, additional, Marcel, Virginie, additional, Diaz, Jean Jacques, additional, Treilleux, Isabelle, additional, Pérol, David, additional, Fabbro, Michel, additional, and Ray-Coquard, Isabelle, additional
Published: 2022
Full Text: View/download PDF

33. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: Philippe Follana, Pierre Combe, Eric Pujade-Lauraine, Alexandra Leary, Patrick Robelin, Gilles Freyer, Michel Fabbro, Nathalie Bonichon-Lamichhane, Christophe Desauw, Olivier Colomban, Christophe Louvet, Jean-Emmanuel Kurtz, Gwenael Ferron, M. Leheurteur, Annick Chevalier-Place, Benoit You, Gaëtan de Rauglaudre, Isabelle Ray-Coquard, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Florence Joly, Francesco Del Piano, and Michel Tod
Subjects: Adult, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Logistic regression, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Elimination rate constant, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, In patient, 030212 general & internal medicine, Aged, Neoplasm Staging, Ovarian Neoplasms, Chemotherapy, business.industry, Cytoreduction Surgical Procedures, Middle Aged, medicine.disease, Debulking, Neoadjuvant Therapy, Progression-Free Survival, Regimen, chemistry, Drug Resistance, Neoplasm, CA-125 Antigen, 030220 oncology & carcinogenesis, Female, Nintedanib, Ovarian cancer, business
Abstract: Purpose: In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMination rate constant K (KELIM), calculated with the CA-125 longitudinal kinetics during the first 100 chemotherapy days, is a validated early marker of tumor chemosensitivity. The objective was to investigate the role of the chemosensitivity relative to the success of first-line medical–surgical treatment. Experimental Design: The CA-125 concentrations were prospectively measured in the randomized phase II trial CHIVA (NCT01583322, carboplatin–paclitaxel regimen ± nintedanib, and IDS, n = 188 patients). The KELIM predictive value regarding the tumor response rate, likelihood of complete IDS, risk of subsequent platinum-resistant relapse (PtRR), progression-free survival (PFS), and overall survival (OS) was assessed using univariate and multivariate tests. Results: The data from 134 patients were analyzed. KELIM was an independent and major predictor of subsequent PtRR risk, and of survivals. The final logistic regression model, including KELIM [OR = 0.13; 95% confidence interval (CI), 0.03–0.49] and complete IDS (no vs. yes, OR = 0.30; 95% CI, 0.11–0.76) highlights the preponderant role of chemosensitivity on the success of the first-line treatment. In patients with highly chemosensitive diseases, the patient prognosis was driven more by the chemotherapy-induced antitumor effects than by the surgery. Conclusions: The tumor-primary chemosensitivity, assessed by the modeled CA-125 KELIM calculated during neoadjuvant chemotherapy (http://www.biomarker-kinetics.org/CA-125-neo), may be a major parameter to consider for decision-making regarding IDS attempt, and selecting patients for treatments meant to reverse the primary chemoresistance. See related commentary by May and Oza, p. 4432
Published: 2020

34. 1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO

Author: S Moret, M. Leheurteur, Annick Chevalier-Place, L. Venat-Bouvet, Philippe Follana, Alexandra Leary, Jean-Pierre Lotz, Laure Favier, Sophie Abadie-Lacourtoisie, F Del Piano, Jérôme Meunier, C. Louvet, Benoit You, Anne Floquet, Olivier Colomban, G. De Rauglaudre, Pierre Combe, Carol Alliot, J Pierre-Alexandre, and N. Raban
Subjects: Oncology, medicine.medical_specialty, Chemotherapy, business.industry, Tumor-infiltrating lymphocytes, medicine.medical_treatment, Cancer, Immunotherapy, Debulking, medicine.disease, chemistry.chemical_compound, Isolated Tumor Cells, chemistry, Internal medicine, Ovarian carcinoma, medicine, Nintedanib, business
Abstract: Introduction/Background* As stated by ESGO-ESMO, there is a need for indicators of chemotherapy efficacy in ovarian carcinoma patients treated in first-line setting (Colombo et al, IGCS, 2020). The pathological chemotherapy response score (CRS) and the modeled CA-125 KELIM during neo-adjuvant chemotherapy were reported as potential markers. Moreover, changes in tumor infiltrating lymphocytes (TILs) after neo-adjuvant chemotherapy were reported as a prognostic factor (Leary et al, Cancer Immunol Immunother, 2021). We studied the relationships between changes in TILs, the pathological response (pR) and KELIM in patients treated with neo-adjuvant chemotherapy +/- interval debulking surgery (IDS) from CHIVA phase II trial. Methodology The patients were enrolled in the randomized phase II trial CHIVA (NCT01583322, neo-adjuvant carboplatin-paclitaxel +/- nintedanib, +/- IDS, n=188 patients). KELIM were previously calculated (You et al CCR 2020). The 30 patients with the highest KELIM (very chemosensitive) or the lowest KELIM (poorly chemosensitive) were selected. HE-stained sections from available tissue blocks at baseline and after chemotherapy were analyzed for stromal TILs (sTILs, surface of the tumor stroma occupied by lymphocytes) and intra-epithelial TILs (ieTILs, brisk or non-brisk). The pathological response (pR) was assessed on the most tumoral available tissue block obtained after chemotherapy (good response if extensive fibrous changes with no or isolated tumor cells, or Result(s)* No relationships between KELIM and TILs infiltrates on baseline tumor samples were found. However, strong associations were found between KELIM and TIL infiltrates after neo-adjuvant chemotherapy for sTILs (median KELIM for sTILs 0-5% vs >5%: 0.28 versus 1.32, P Conclusion* High consistency was found between the modeled CA125 KELIM calculated during the first 100 days of neo-adjuvant chemotherapy and the pathological response, consistent with their values as indicators of the tumor chemosensitivity in first-line setting. Moreover, TILs changes were strongly associated with chemosensitivity, opening hypotheses about the mechanisms of chemosensitivity, and immunotherapy opportunity.
Published: 2021

35. 1032 Strong association between pathological response to neoadjuvant chemotherapy, TILs and modeled CA125 KELIM in ovarian carcinomas: CHIVA trial, GINECO

Author: Pierre-Alexandre, J, primary, Moret, S, additional, Colomban, O, additional, Combe, P, additional, Abadie-Lacourtoisie, S, additional, Meunier, J, additional, Floquet, A, additional, Venat-Bouvet, L, additional, Louvet, C, additional, Favier, L, additional, Follana, P, additional, Lotz, JP, additional, Del Piano, F, additional, Leheurteur, M, additional, Alliot, CR, additional, De Rauglaudre, G, additional, Raban, N, additional, Chevalier-Place, A, additional, Leary, A, additional, and You, B, additional
Published: 2021
Full Text: View/download PDF

36. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Author: Pierre, Heudel, Jean-Sébastien, Frenel, Cécile, Dalban, Fernando, Bazan, Florence, Joly, Antoine, Arnaud, Cyril, Abdeddaim, Annick, Chevalier-Place, Paule, Augereau, Patricia, Pautier, Camille, Chakiba, Benoit, You, Laurence, Lancry-Lecomte, Gwenaelle, Garin, Virginie, Marcel, Jean Jacques, Diaz, Isabelle, Treilleux, David, Pérol, Michel, Fabbro, and Isabelle, Ray-Coquard
Subjects: Cancer Research, Morpholines, TOR Serine-Threonine Kinases, Breast Neoplasms, MTOR Inhibitors, Anastrozole, Endometrial Neoplasms, Phosphatidylinositol 3-Kinases, Pyrimidines, Oncology, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Female, Aged, Original Investigation
Abstract: IMPORTANCE: Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy. OBJECTIVE: To evaluate the safety and efficacy of vistusertib in combination with anastrozole in the treatment of women with hormone receptor−positive recurrent or metastatic endometrial cancer. DESIGN, SETTINGS, AND PARTICIPANTS: The VICTORIA study was a multicenter, open-label, randomized clinical trial that accrued 75 patients with hormone receptor−positive recurrent or metastatic endometrial cancer from 12 cancer centers in France in April 2016 to October 2019. After a safety run-in period, a Simon 2-stage design was used. Data analyses were performed from December 11, 2020, to March 11, 2021. INTERVENTIONS: Patients were randomized in a 2:1 ratio to oral vistusertib (125 mg twice daily 2 days per week) and oral anastrozole (1 mg daily) in the combination vistusertib with anastrozole arm (V+A arm) or oral anastrozole alone (A arm). MAIN OUTCOMES AND MEASURES: The primary end point was serious adverse events for the safety run-in period and progression-free rate at 8 weeks (8wk-PFR)—assessed with a blinded independent central review in phase 2. The secondary end points were objective response rate, duration of response, progression-free survival (PFS), overall survival, and incidence of adverse events. RESULTS: Of the 75 patients who were randomized, 73 (median [range] age, 69.5 [37-88] y; all female) were treated: V+A arm, 49 patients; A arm, 24 patients. In the V+A arm, the 8wk-PFR was 67.3% (unilateral 95% CI, 54.7%) and in the A arm, 39.1% (unilateral 95% CI, 22.2%). No significant serious adverse events were reported during the safety run-in period (n = 6 in V+A arm). The overall response rate was 24.5% (95% CI, 13.3%-38.9%) in the V+A arm vs 17.4% (95% CI, 5.0%-38.8%) in the A arm. With a median follow-up of 27.7 months, median PFS was 5.2 (95% CI, 3.4-8.9) in the V+A arm and 1.9 (95% CI, 1.6-8.9) months in the A arm. Fatigue, lymphopenia, hyperglycemia, and diarrhea were the most common (grade ≥2) adverse events associated with vistusertib. CONCLUSIONS AND RELEVANCE: This multicenter, open-label, phase 1/2 randomized clinical trial demonstrated that adding vistusertib to anastrozole improved 8wk-PFR, overall response rate, and PFS for patients with endometrial cancer and had manageable adverse events. Identification of molecular subgroups would allow for more precise selection of patients who may be most likely to experience favorable outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02730923
Published: 2022

37. Standards, Options et Recommandations 2006. Prise en charge des patients adultes atteints de sarcome des tissus mous, de sarcome utérin ou de tumeur stromale gastro-intestinale

Author: Bui, B. -N., Blay, J. -Y., Bonichon, F., Bonvalot, S., Chevalier-Place, A., Coindre, J. -M., Delannes, M., Le Cesne, A., Morice, P., Ray-Coquard, I., Pautier, P., Le Péchoux, C., Stöeckle, E., Taieb, S., and Bosquet, L.
Published: 2007
Full Text: View/download PDF

38. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Author: Jérôme Meunier, Florence Joly, Joël Lachuer, E. Malaurie, Marie-Christine Kaminsky, Dominique Berton-Rigaud, Jérôme Alexandre, Gaëtan de Rauglaudre, Coraline Dubot, Michel Tod, Patrick Robelin, Olivier Colomban, Alexandra Leary, Gwenael Ferron, Isabelle Ray-Coquard, Alain Lortholary, Annick Chevalier-Place, Salima Hamizi, Benoit You, N. Raban, Pierre Combe, Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital de la Croix-Rousse [CHU - HCL], Santé Lyon Est - Louis Léopold Ollier, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), ProfileXpert, Université de Lyon, Centre Léon Bérard [Lyon], Institut Sainte Catherine [Avignon], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital privé du Confluent [Nantes], Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Institut Claudius Regaud, Centre Hospitalier Régional d'Orléans (CHRO), CRLCC René Gauducheau, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, CRLCC René Huguenin, Institut Gustave Roussy (IGR), CHI Créteil, Laboratoire Joliot Curie, École normale supérieure - Lyon (ENS Lyon)-Centre National de la Recherche Scientifique (CNRS), Institut Jacques Monod (IJM (UMR_7592)), Université de Paris (UP)-Centre National de la Recherche Scientifique (CNRS), Centre Alexis Vautrin (CAV), Oncologie gynécologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), and Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)
Subjects: 0301 basic medicine, Circulating mirnas, Oncology, Indoles, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, ComputingMilieux_MISCELLANEOUS, Ovarian Neoplasms, ca125, Obstetrics and Gynecology, Cytoreduction Surgical Procedures, Middle Aged, Debulking, Prognosis, Predictive value, Neoadjuvant Therapy, Progression-Free Survival, 3. Good health, 030220 oncology & carcinogenesis, Nintedanib, Female, Adult, medicine.medical_specialty, Paclitaxel, 03 medical and health sciences, Ovarian cancer, Predictive Value of Tests, Internal medicine, microRNA, Biomarkers, Tumor, Chemotherapy, Humans, Circulating MicroRNA, Response Evaluation Criteria in Solid Tumors, miRNA, Aged, business.industry, Membrane Proteins, medicine.disease, First line treatment, Kinetics, 030104 developmental biology, chemistry, CA-125 Antigen, business, Biomarkers
Abstract: International audience; Objective: MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with peri-operative chemotherapy and interval debulking surgery (IDS).Methods: Serial blood samples of patients enrolled in the randomized phase II CHIVA trial, comparing first line carboplatin-paclitaxel +/- nintedanib (NCT01583322) and IDS, were investigated to assess the kinetics of 11 relevant miRNAs. Their prognostic/predictive values regarding the likelihood of complete IDS, and the patient survival, were assessed and compared to those of CA125 kinetics. The selection of the miRNAs (miR-15b-5p, miR-16-5p, miR-20a-5p, miR-21-5p, miR-93-5p, miR-122-5p, miR-150-5p, miR-195-5p, miR-200b-3p, miR-148b-5p and miR-34a-5p) was based on the expression levels found with a large explorative panel, and on the literature data.Results: 756 serial blood samples from 119 patients were analyzed for a total of 8172 miRNA assays, and 1299 CA125 values. The longitudinal kinetics of the miRNA expressions were highly inconsistent, and were not related to CA125 dynamics. The miRNA changes during neoadjuvant treatment were not found associated with RECIST tumor response or IDS outcomes. Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests.Conclusions: The longitudinal kinetics of miRNA expressions during neoadjuvant treatment in ovarian cancer patients were inconsistent, and were not found to be associated with tumor burden changes. Although some prognostic value could be discussed, no predictive value regarding tumor responses or IDS quality could be identified.
Published: 2020

39. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors

Author: Ray-Coquard, Isabelle, primary, Harter, Philipp, additional, Lorusso, Domenica, additional, Dalban, Cécile, additional, Vergote, Ignace, additional, Fujiwara, Keiichi, additional, Gladieff, Laurence, additional, Lück, Hans-Joachim, additional, Floquet, Anne, additional, Chevalier-Place, Annick, additional, Schnelzer, Andreas, additional, Pignata, Sandro, additional, Selle, Frédéric, additional, Sehouli, Jalid, additional, Brocard, Fabien, additional, Mangili, Giorgia, additional, Pautier, Patricia, additional, De Giorgi, Ugo, additional, Provansal, Magali, additional, and Heudel, Pierre-Etienne, additional
Published: 2020
Full Text: View/download PDF

40. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Author: You, Benoit, primary, Robelin, Patrick, additional, Tod, Michel, additional, Louvet, Christophe, additional, Lotz, Jean-Pierre, additional, Abadie-Lacourtoisie, Sophie, additional, Fabbro, Michel, additional, Desauw, Christophe, additional, Bonichon-Lamichhane, Nathalie, additional, Kurtz, Jean-Emmanuel, additional, Follana, Philippe, additional, Leheurteur, Marianne, additional, Piano, Francesco Del, additional, Ferron, Gwénael, additional, De Rauglaudre, Gaëtan, additional, Ray-Coquard, Isabelle, additional, Combe, Pierre, additional, Chevalier-Place, Annick, additional, Joly, Florence, additional, Leary, Alexandra, additional, Pujade-Lauraine, Eric, additional, Freyer, Gilles, additional, and Colomban, Olivier, additional
Published: 2020
Full Text: View/download PDF

41. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors

Author: C. Dalban, Laurence Gladieff, Jalid Sehouli, Giorgia Mangili, Magali Provansal, Ugo De Giorgi, Isabelle Ray-Coquard, Hans Joachim Lück, Fabien Brocard, Andreas Schnelzer, Sandro Pignata, Keiichi Fujiwara, Annick Chevalier-Place, Philipp Harter, Patricia Pautier, Domenica Lorusso, Pierre Heudel, Ignace Vergote, Anne Floquet, and Frédéric Selle
Subjects: Oncology, Cancer Research, medicine.medical_specialty, Paclitaxel, Combination therapy, Bevacizumab, medicine.medical_treatment, Disease-Free Survival, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Interquartile range, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Sex Cord-Gonadal Stromal Tumors, Medicine, 030212 general & internal medicine, Original Investigation, Chemotherapy, business.industry, Bayes Theorem, chemistry, 030220 oncology & carcinogenesis, Toxicity, Female, Neoplasm Recurrence, Local, business, Sex Cord-Stromal Tumor, medicine.drug
Abstract: Importance To our knowledge, this is the first randomized trial in sex cord-stromal tumors, and it establishes weekly paclitaxel as standard-of-care therapy after platinum-based therapy in this setting. Objective To determine the efficacy of weekly paclitaxel with or without bevacizumab as treatment for relapsed sex cord-stromal tumors and evaluate whether the addition of bevacizumab to weekly paclitaxel improves 6-month progression-free rate. Design, setting, and participants This open-label, academic, international, randomized phase 2 trial (ALIENOR) was conducted at 28 referral centers in France, Germany, Italy, Japan, and Belgium in collaboration with the Rare Tumor committee of the Gynecologic Cancer InterGroup and used an adaptive bayesian design. It included 60 women with sex cord-stromal tumors that had relapsed after at least 1 platinum-based chemotherapy. Enrollment occurred from 2013 to 2016, and the final analysis database lock was on March 27, 2020 (median follow-up, 38.9 months). Interventions Participants were randomized to receive either paclitaxel (80 mg/m2, days 1, 8, and 15 every 4 weeks) alone or paclitaxel with bevacizumab (10 mg/kg, every 2 weeks) for 6 cycles followed by maintenance bevacizumab (15 mg/kg, every 3 weeks) for up to 1 year or until progression or unacceptable toxicity. Crossover to bevacizumab was permitted after progression during or following paclitaxel alone. Main outcomes and measures Six-month progression-free rate. Results Sixty patients (predominantly with granulosa cell tumors) were randomized, 32 to receive single-agent paclitaxel (median [interquartile range] age at inclusion, 60 [53-64] years) and 28 to receive paclitaxel-bevacizumab (median [interquartile range] age at inclusion, 55 [47-61] years; 1 did not receive treatment). The estimated 6-month progression-free rate was 71% (95% credible interval, 55%-84%) with paclitaxel alone and 72% (95% credible interval, 55%-87%) with paclitaxel-bevacizumab. The bayesian estimate for the probability that the 6-month progression-free rate distribution was higher with the combination than with paclitaxel alone was 57%, less than the predefined superiority threshold. The objective response rate increased from 25% (95% CI, 12%-43%) to 44% (95% CI, 26%-65%) with the addition of bevacizumab. One patient discontinued combination therapy within 6 months because of toxicity. Conclusions and relevance Weekly paclitaxel is a new option for relapsed sex cord-stromal tumors. In this international randomized clinical trial of patients with relapsed sex cord-stromal tumors unsuitable for surgery, adding bevacizumab to weekly paclitaxel does not improve clinical benefit. Trial registration ClinicalTrials.gov Identifier: NCT01770301.
Published: 2020

42. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Author: Despierre, Evelyn, Vergote, Ignace, Anderson, Ryan, Coens, Corneel, Katsaros, Dionyssios, Hirsch, Fred R., Boeckx, Bram, Varella Garcia, Marileila, Ferrero, Annamaria, Ray Coquard, Isabelle, Berns, Els M. J. J., Casado, Antonio, Lambrechts, Diether, Jimeno, Antonio, Abraham, C, Chesnay, L, Amant, F, Anderson, R, Azzedine, A, Benedetto, Chiara, Bertelli, G, Berteloot, P, Berton Rigaud, D, Biglia, N, Bonichon Lamichhane, N, Bougnoux, P, Bourbouloux, E, Bourcier, C, Buck, M, Campone, M, Canuto, Em, Casado Herraez, A, Cauvin, I, Chauvenet, L, Chevalier Place, A, Cottu, P., Cretin, J, Cumin, I, Curé, H, Dalenc, F, Danese, S, Davis, A, Debruyne, P, Delplanque, G, Delva, R, D'Hondt, V, Dramais, D, Durando, X, El Kouri, C, Esteban, C, Fabbro, M, Falandry, C, Filleul, B, Floquet, A, Fumoleau, P, Garcia Varella, M, Garnier, C, Gilby, E, Gladieff, L, Goffin, F, Gouttebel, M., Green, Ja, Guastalla, J., Hardy Bessard, A., Hirsch, F, Hughes, A, Jaubert, D, Kaminsky, M., Katsaros, D, Largillier, R, Lebrun Jezekova, D, Leduc, B, Leheurteur, M, Lesoin, A, Leunen, K, Levasseur, N, Leyronnas, C, Llory, J., Lortholary, A, Mayer, F, Mayeur, D, Mendiola, C, Mignot, L, Morgan, J, Mouret Reynier, M., Neven, P, Petit, T, Picardo, E, Plaza, J, Pluvio Coronado, M, Priou, F, Pujade Lauraine, E, Coquard, I, Reed, N, Rigault de la Longrais, I, Scholl, S, Sillet Bach, I, Steer, C, Summers, J, Trillet Lenoir, V, Van Dam, P, Van Der Burg ME, Vanlerenberghe, E, Vannetzel, J., Vergote, I, Aragon, Ja, Waters, J, Weber, B, Yazbek, G, Zola, P., Medical Oncology, and Other departments
Subjects: Neuroblastoma RAS viral oncogene homolog, Oncology, Adult, Cancer Research, medicine.medical_specialty, Organoplatinum Compounds, medicine.disease_cause, Article, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Disease Progression, Disease-Free Survival, Erlotinib Hydrochloride, Female, Humans, Middle Aged, Mutation, Ovarian Neoplasms, Protein Kinase Inhibitors, Protein Kinases, Receptor, Epidermal Growth Factor, Pharmacology (medical), SDG 3 - Good Health and Well-being, Internal medicine, 80 and over, Medicine, EGFR Gene Amplification, Epidermal growth factor receptor, neoplasms, Tumor, Epidermal Growth Factor, biology, business.industry, Cancer, medicine.disease, ErbB Receptors, biology.protein, Biomarker (medicine), Erlotinib, KRAS, business, Ovarian cancer, Biomarkers, Receptor, medicine.drug
Abstract: In this work, we aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in patients with ovarian cancer who were treated within the phase III randomized European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG) 55041 study comparing erlotinib with observation in patients with no evidence of disease progression after first-line platinum-based chemotherapy. Somatic mutations in KRAS, BRAF, NRAS, PIK3CA, EGFR, and PTEN were determined in 318 (38 %) and expression of EGFR, pAkt, pMAPK, E-cadherin and Vimentin, and EGFR and HER2 gene copy numbers in 218 (26 %) of a total of 835 randomized patients. Biomarker data were correlated with progression-free survival (PFS) and overall survival (OS). Only 28 mutations were observed among KRAS, BRAF, NRAS, PIK3CA, EGFR, and PTEN (in 7.5 % of patients), of which the most frequent were in KRAS and PIK3CA. EGFR mutations occurred in only three patients. When all mutations were pooled, patients with at least one mutation in KRAS, NRAS, BRAF, PIK3CA, or EGFR had longer PFS (33.1 versus 12.3 months; HR 0.57; 95 % CI 0.33 to 0.99; P = 0.042) compared to those with wild-type tumors. EGFR overexpression was detected in 93 of 218 patients (42.7 %), and 66 of 180 patients (36.7 %) had EGFR gene amplification or high levels of copy number gain. Fifty-eight of 128 patients had positive pMAPK expression (45.3 %), which was associated with inferior OS (38.9 versus 67.0 months; HR 1.81; 95 % CI 1.11 to 2.97; P = 0.016). Patients with positive EGFR fluorescence in situ hybridization (FISH) status had worse OS (46.1 months) than those with negative status (67.0 months; HR 1.56; 95 % CI 1.01 to 2.40; P = 0.044) and shorter PFS (9.6 versus 16.1 months; HR 1.57; 95 % CI 1.11 to 2.22; P = 0.010). None of the investigated biomarkers correlated with responsiveness to erlotinib. In this phase III study, increased EGFR gene copy number was associated with worse OS and PFS in patients with ovarian cancer. It remains to be determined whether this association is purely prognostic or is also predictive.
Published: 2015

43. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study

Author: Hugues Bourgeois, F. Mayer, Patricia Pautier, E. Guardiola, Michel Henry-Amar, Thierry Petit, R. Delva, Emmanuel Sevin, Florence Joly, and Annick Chevalier-Place
Subjects: Adult, Oncology, medicine.medical_specialty, medicine.medical_treatment, Phases of clinical research, Neutropenia, Deoxycytidine, Drug Administration Schedule, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Infusions, Intravenous, Aged, Aged, 80 and over, Ovarian Neoplasms, Chemotherapy, Taxane, business.industry, Obstetrics and Gynecology, Middle Aged, medicine.disease, Gemcitabine, Treatment Outcome, Quality of Life, Female, Topotecan, Ovarian cancer, business, medicine.drug
Abstract: Objectives The aim of this phase II study was to assess the benefits of a weekly administration of topotecan and gemcitabine in patients with ovarian carcinoma having relapsed after platinum/taxane-based first-line chemotherapy. Methods Seventy-seven patients with progression of disease ≤12 months after first-line chemotherapy were enrolled to receive topotecan (2.5 mg/m 2 ) and gemcitabine (1000 mg/m 2 ) on days 1, 8 and 15 (q 28 d). Primary endpoint was the response rate. Stabilization rate and symptom improvement were also assessed. Results All patients received the combination and 66 were evaluable (≥2 cycles administered). The only major severe toxicity was neutropenia grades 3 (17%) and 4 (6%). Approximately 60% of the patients received the complete schedule of treatment, dose interruptions/delays being mainly due to moderate thrombocytopenia or neutropenia. The objective response rate was 14%, the values for patients having relapsed within 6 ( n =30) and 6–12 ( n =36) months being 7% and 20%, respectively. Median durations of response were 4.9 and 6.4 months and clinical benefit rates including stabilizations reached 63% and 69% in patients having relapsed within 6 or 6–12 months, respectively. Corresponding median overall survival was 7.5 and 15.6 months. Symptoms and pain were reduced in 64% and 39% of the patients concerned, respectively. Conclusion In early relapse ovarian cancer, weekly combination of gemcitabine and topotecan has a modest objective response rate. However, a high proportion of patients experienced stable disease and symptom control leading to acceptable quality of life.
Published: 2009

44. Clinical practice guidelines: 2006. Update of recommendations for the management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma

Author: P. Morice, A. Chevalier-Place, I.L. Ray-Coquard, Patricia Pautier, S. Bonvalot, C. Le Pechoux, Françoise Bonichon, B. Bui, L. Bosquet, M. Delannes, Sophie Taïeb, A. Le Cesne, J.-M. Coindre, E. Stoeckle, and J.-Y. Blay
Subjects: Oncology
Abstract: Contexte La mise a jour des recommandations pour la pratique clinique (RPC) pour la prise en charge des patients atteints d’un sarcome des tissus mous a ete elaboree par la Federation nationale des centres de lutte contre le cancer (FNCLCC), en collaboration avec le Groupe sarcome francais et le Groupe d’etude des tumeurs osseuses (GSF-GETO), des partenaires des secteurs publics (CHU, CHG), prive et de l’Institut national du cancer sur la base de la methodologie developpee par les SOR.
Published: 2007

45. Recommandations pour la pratique clinique : mise à jour 2006 des Standards, Options et Recommandations pour l'irradiation des patients adultes atteints de sarcome des tissus mous (sarcome des membres, sarcomes rétropéritonéaux et sarcomes utérins)

Author: Recommandations, A. Chevalier-Place, A. Le Cesne, Françoise Bonichon, I.L. Ray-Coquard, Fédération Française de Cancérologie, Patricia Pautier, Sophie Taïeb, P. Morice, B. Bui, S. Bonvalot, J.-M. Coindre, E. Stoeckle, Standards Options, M. Delannes, Lique Contre Le Cancer, Fnchru, and C. Le Pechoux
Subjects: medicine.medical_specialty, Soft Tissue Neoplasm, Uterine sarcoma, business.industry, General surgery, Soft tissue sarcoma, MEDLINE, Context (language use), Guideline, medicine.disease, Critical appraisal, Oncology, Medicine, Radiology, Nuclear Medicine and imaging, Sarcoma, business
Abstract: Context The National French Federation of Comprehensive Cancer Centres (FNCLCC) initiated the update of clinical practice guideline for the management of patients with soft tissue sarcoma in collaboration with the French Sarcoma Group (GSF-GETO), specialists from French public universities, general hospitals and private clinics and with the French National Cancer Institute. This work is based on the methodology developed in the "Standards, Options and Recommendations" (SOR) project. Objectives To update SOR guidelines for the management of patients with soft tissue sarcoma previously validated in 1995. Methods The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts who define the CPGsaccording to the definitions of the Standards, Options and Recommendations project. Once the guidelines have been developed, they are reviewed by independent reviewers. Results This article presents the updated recommendations for radiotherapeutic management. The main recommendations are: 1) irradiation before or after surgical treatment is the standard for soft tissue sarcoma of the extremity and uterine sarcoma; 2) no systematic irradiation should be done in case of retroperitoneal sarcoma.
Published: 2006

46. Carcinome à petites cellules de l'ovaire hypercalcémiant révélé par un épisode de pancréatite aiguë : à propos d'un cas

Author: M. C. Baranzelli, A. Bourgain, Eric Lambaudie, J.-L. Wemeau, O. Acker, Denis Querleu, P. Meignie, Malik Boukerrou, M. Parent, V. Cabaret, and A. Chevalier-Place
Subjects: Pathology, medicine.medical_specialty, Pancreatic disease, business.industry, Obstetrics and Gynecology, Ovary, General Medicine, medicine.disease, Small-cell carcinoma, Ovarian Small Cell Carcinoma, Lesion, medicine.anatomical_structure, Reproductive Medicine, Carcinoma, medicine, Acute pancreatitis, Pancreatitis, medicine.symptom, business
Abstract: Small cell carcinoma of the ovary of the hypercalcemic type is a rare tumour, usually lethal and occurring almost exclusively in young patients. In the majority of described cases, signs of this lesion were revealed by the associated hypercalcemia or by virtue of the physical tumour bulk alone. We report the first case of ovarian small cell carcinoma of the hypercalcemic revealed by a severe acute pancreatitis in a 19-year-old patient.
Published: 2005

47. Neuroendocrine tumors of the uterine cervix

Author: Pierre Collinet, Denis Querleu, Eric Leblanc, Damienne Declerck, D. Lanvin, and Annick Chevalier-Place
Subjects: medicine.medical_specialty, Chemotherapy, Hysterectomy, business.industry, medicine.medical_treatment, Obstetrics and Gynecology, Combination chemotherapy, Neuroendocrine tumors, medicine.disease, Small-cell carcinoma, Surgery, Radiation therapy, medicine.anatomical_structure, Reproductive Medicine, medicine, Combined Modality Therapy, business, Cervix
Abstract: Four main clinicopathologic features of neuroendocrine tumors (NETs) of the cervix may be stressed: primary diagnosis at an advanced stage, early nodal metastasis even for low disease, early failure of appropriate local treatment (surgery and/or radiation therapy) and aggressive clinical treatment. Five patients with NET of the uterine cervix (small cell carcinoma type) are reported (one stage I, two stages II, one stage III and one stage IV). One patient was treated by surgery combined with radiation therapy, one by surgery combined with chemotherapy and one by surgery with radiation therapy and chemotherapy. Two patients received radiation therapy alone. Three early stage patients are alive with no evidence of disease 8, 26 and 41 months after diagnosis. The two patients with advanced stage died of disease, 3 and 12 months respectively, after diagnosis. Combination chemotherapy (cisplatin and etoposide) is warranted in disseminated NETs. Neoadjuvant or adjuvant chemotherapy should be combined with radiation therapy and surgery even in early stages.
Published: 2000

48. [Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma]

Author: C, Le Péchoux, P, Pautier, M, Delannes, B N, Bui, F, Bonichon, S, Bonvalot, A, Chevalier-Place, J-M, Coindre, A, Le Cesne, P, Morice, I, Ray-Coquard, E, Stöeckle, and S, Taieb
Subjects: Brachytherapy, Radiotherapy Dosage, Sarcoma, Soft Tissue Neoplasms, Neoadjuvant Therapy, Upper Extremity, Lower Extremity, Uterine Neoplasms, Humans, Female, Radiotherapy, Adjuvant, France, Retroperitoneal Neoplasms, Neoplasm Recurrence, Local
Abstract: The National French Federation of Comprehensive Cancer Centres (FNCLCC) initiated the update of clinical practice guideline for the management of patients with soft tissue sarcoma in collaboration with the French Sarcoma Group (GSF-GETO), specialists from French public universities, general hospitals and private clinics and with the French National Cancer Institute. This work is based on the methodology developed in the "Standards, Options and Recommendations" (SOR) project.To update SOR guidelines for the management of patients with soft tissue sarcoma previously validated in 1995.The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts who define the CPGsaccording to the definitions of the Standards, Options and Recommendations project. Once the guidelines have been developed, they are reviewed by independent reviewers.This article presents the updated recommendations for radiotherapeutic management. The main recommendations are: 1) irradiation before or after surgical treatment is the standard for soft tissue sarcoma of the extremity and uterine sarcoma; 2) no systematic irradiation should be done in case of retroperitoneal sarcoma.
Published: 2006

49. [Small cell carcinoma of the ovary of the hypercalcemic type revealed by a severe acute pancreatitis: about one case]

Author: A, Bourgain, O, Acker, E, Lambaudie, M, Boukerrou, A, Chevalier-Place, P, Meignie, M, Parent, M-C, Baranzelli, V, Cabaret, J-L, Wemeau, and D, Querleu
Subjects: Adult, Ovarian Neoplasms, Fatal Outcome, Pancreatitis, Acute Disease, Hypercalcemia, Humans, Female, Carcinoma, Small Cell, Tomography, X-Ray Computed
Abstract: Small cell carcinoma of the ovary of the hypercalcemic type is a rare tumour, usually lethal and occurring almost exclusively in young patients. In the majority of described cases, signs of this lesion were revealed by the associated hypercalcemia or by virtue of the physical tumour bulk alone. We report the first case of ovarian small cell carcinoma of the hypercalcemic revealed by a severe acute pancreatitis in a 19-year-old patient.
Published: 2004

50. Neuroendocrine tumors of the uterine cervix. Clinicopathologic study of five patients

Author: P, Collinet, D, Lanvin, D, Declerck, A, Chevalier-Place, E, Leblanc, and D, Querleu
Subjects: Adult, Aged, 80 and over, Neuroendocrine Tumors, Antineoplastic Combined Chemotherapy Protocols, Humans, Uterine Cervical Neoplasms, Female, Carcinoma, Small Cell, Middle Aged, Hysterectomy, Combined Modality Therapy, Aged
Abstract: Four main clinicopathologic features of neuroendocrine tumors (NETs) of the cervix may be stressed: primary diagnosis at an advanced stage, early nodal metastasis even for low disease, early failure of appropriate local treatment (surgery and/or radiation therapy) and aggressive clinical treatment. Five patients with NET of the uterine cervix (small cell carcinoma type) are reported (one stage I, two stages II, one stage III and one stage IV). One patient was treated by surgery combined with radiation therapy, one by surgery combined with chemotherapy and one by surgery with radiation therapy and chemotherapy. Two patients received radiation therapy alone. Three early stage patients are alive with no evidence of disease 8, 26 and 41 months after diagnosis. The two patients with advanced stage died of disease, 3 and 12 months respectively, after diagnosis. Combination chemotherapy (cisplatin and etoposide) is warranted in disseminated NETs. Neoadjuvant or adjuvant chemotherapy should be combined with radiation therapy and surgery even in early stages.
Published: 2000

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

106 results on '"Chevalier-Place, A."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources